Astrana Health Inc. (ASTH) valuation against sector peers: P/E 50.5 (sector median 30.1), P/B 2.5, EV/EBIT 35.4, free-cash-flow yield 4.6%, P/S 0.5.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	ASTH	Sector median	vs median
P/E	50.5	30.1 · n=150	68% above
P/B	2.5	3.9 · n=304	37% below
P/S	0.5	4.2 · n=297	87% below
EV/EBIT	35.4	25.8 · n=140	37% above
Free-cash-flow yield	4.6%	1.4% · n=289	219% above
Dividend yield	0.00%	0.00% · n=361	—
Return on equity	5.1%	−3.7% · n=306	—
Return on invested capital	3.7%	0.5% · n=276	588% above
Gross margin	10.5%	62.4% · n=204	83% below
Net debt / EBITDA	9.15	1.30 · n=145	606% above

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Value factor: 72 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	48.1	32.9	—	1.5%	0.6%	7/10
JNJJohnson & Johnson	39.8	7.9	—	3.2%	2.0%	8/10
ABBVAbbVie	49.1	—	27.1	3.7%	3.0%	6/10
UNHUnitedHealth	22.8	3.5	17.3	6.3%	2.2%	10/10
MRKMerck	112.5	8.5	—	4.5%	2.4%	9/10
TMOThermo Fisher Scientific	36.6	4.7	34.7	2.9%	0.3%	9/10
AMGNAmgen	28.5	21.3	25.6	4.1%	2.2%	7/10
GILDGilead Sciences	—	15.9	—	6.6%	1.9%	5/10
ABTAbbott	30.2	3.7	28.3	3.9%	2.8%	6/10
PFEPfizer	42.4	1.9	—	6.9%	7.2%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 10 Aug 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings